Ultragenyx Pharmaceutical INC Form 4 insider transactions

Ultragenyx CEO Emil Kakkis sold 11,727 shares of common stock at an average price of $42.23 on December 30, 2024.

A senior executive at Ultragenyx Pharmaceutical Inc. has sold a portion of their common stock holdings.

Ultragenyx CEO Emil Kakkis disposed of 8,273 shares of common stock at $50 per share after receiving a grant of 20,000 shares.

Ultragenyx Pharmaceutical Inc.'s CFO, Howard Horn, sold 7,465 shares of common stock on October 10, 2024, to cover tax withholdings related to vesting RSUs.

Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., reports the acquisition of 700 shares of common stock through a restricted stock unit (RSU) award.

Ultragenyx Pharmaceutical Inc.'s CEO, Emil D. Kakkis, recently sold 20,000 shares of common stock at an average price of $55.85.

Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., sold 91 shares of common stock on September 3, 2024, to cover tax withholdings related to vesting RSUs.

Ultragenyx Pharmaceutical Inc.'s CEO, Emil D. Kakkis, sold 20,000 shares of common stock at an average price of $50.17 on August 6, 2024.

Director Corazon (Corsee) D. Sanders sold 584 shares of Ultragenyx Pharmaceutical Inc. (RARE) common stock at a price of $40.98 on July 2, 2024.

Director Deborah Dunsire reports the acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Director Matthew K. Fust reported the acquisition of restricted stock units and stock options in Ultragenyx Pharmaceutical Inc.

Director Daniel G. Welch reports acquisition of restricted stock units and stock options, along with the disposal of common stock.

Director Michael Narachi acquired stock options and restricted stock units in Ultragenyx Pharmaceutical Inc. on June 18, 2024.

Director Amrit Ray reports acquisition of stock options and restricted stock units in Ultragenyx Pharmaceutical Inc.

Director Corazon Sanders reports acquiring and disposing of Ultragenyx Pharmaceutical Inc. shares, including restricted stock units and stock options.

Director Shehnaaz Suliman reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., sold 9,806 shares of common stock at $45 per share on June 12, 2024.

Director Corazon (Corsee) D. Sanders of Ultragenyx Pharmaceutical Inc. sold 1,737 shares of common stock at a price of $41.1 on June 10, 2024.

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., sold 354 shares of common stock on May 2, 2024, to cover tax withholdings related to vesting RSUs.

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., sold 142 shares of common stock on April 18, 2024, to cover tax withholdings related to vesting RSUs.

Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., disposed of 14 shares of common stock to cover tax withholdings related to vesting RSUs.

Ultragenyx Pharmaceutical's CBO & EVP, Thomas Richard Kassberg, sold 11,509 shares of common stock on March 11, 2024.

Director Matthew K. Fust of Ultragenyx Pharmaceutical Inc. reports selling shares of common stock in a series of transactions on March 7, 2024.

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reports acquisition of common stock and stock options.

Karah Parschauer, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of common stock and stock options.

Thomas Kassberg, CBO & EVP of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of company stock and stock options.

Dennis Karl Huang, an executive at Ultragenyx Pharmaceutical Inc., reports acquisition of shares and stock options, along with the surrender of shares for tax obligations.

John Richard Pinion, an executive at Ultragenyx Pharmaceutical Inc., reported the acquisition and disposal of company stock and derivative securities.

Theodore Alan Huizenga, SVP and Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of common stock and stock options.

EVP and Chief Medical Officer Eric Crombez reports acquisition and disposal of Ultragenyx Pharmaceutical Inc. stock and stock options.